ATE378348T1 - Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion - Google Patents

Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion

Info

Publication number
ATE378348T1
ATE378348T1 AT01902045T AT01902045T ATE378348T1 AT E378348 T1 ATE378348 T1 AT E378348T1 AT 01902045 T AT01902045 T AT 01902045T AT 01902045 T AT01902045 T AT 01902045T AT E378348 T1 ATE378348 T1 AT E378348T1
Authority
AT
Austria
Prior art keywords
oligodeoxynucleotides
inducing
immune response
compositions
individuals
Prior art date
Application number
AT01902045T
Other languages
English (en)
Inventor
Dennis Klinman
Ken Ishii
Daniela Verthelyi
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE378348T1 publication Critical patent/ATE378348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT01902045T 2000-01-14 2001-01-12 Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion ATE378348T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17611500P 2000-01-14 2000-01-14

Publications (1)

Publication Number Publication Date
ATE378348T1 true ATE378348T1 (de) 2007-11-15

Family

ID=22643035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902045T ATE378348T1 (de) 2000-01-14 2001-01-12 Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion

Country Status (6)

Country Link
US (3) US7521063B2 (de)
EP (1) EP1322655B1 (de)
AT (1) ATE378348T1 (de)
AU (1) AU2001227889A1 (de)
DE (1) DE60131430T2 (de)
WO (1) WO2001051500A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
EP1322655B1 (de) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
EP1335741A4 (de) * 2000-08-25 2005-10-26 Yeda Res & Dev METHODE ZUR PRÄVENTION VON AUTOIMMUNKRANKHEITEN MIT CpG-ENTHALTENDEN POLYNUCLEOTIDEN(04.03.02)
NZ526322A (en) 2000-12-27 2005-06-24 Dynavax Tech Corp Immunomodulatory polynucleotides and methods of using the same
EP1404873B1 (de) 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimäre immunmodulatorische verbindungen und verfahren zu deren verwendung
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP1572122A4 (de) 2002-11-01 2008-04-09 Us Gov Health & Human Serv Verfahren zur vorbeugung gegen infektionen von bioterrorismus-agentien mit immunstimulierenden cpg-oligonukleotiden
JP2006512927A (ja) * 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
ATE544772T1 (de) 2002-12-23 2012-02-15 Dynavax Tech Corp Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
KR100681470B1 (ko) * 2003-03-03 2007-02-12 연세대학교 산학협력단 면역반응 증진용 올리고뉴크레오타이드
CA2526690C (en) 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
MXPA05013658A (es) 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
CN101454451A (zh) * 2003-10-30 2009-06-10 科勒制药有限公司 具有增强免疫刺激能力的c类寡核苷酸类似物
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2009156960A2 (en) 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
ES2352780B2 (es) 2009-06-04 2011-09-15 Laboratorios Ovejero S.A. Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
WO2013162828A1 (en) * 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
UA121200C2 (uk) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP3238727B1 (de) * 2014-12-25 2023-01-18 National Institutes of Biomedical Innovation, Health and Nutrition Nichtaggregierende immunstimulierende oligonukleotide
EP4248992A3 (de) 2015-01-16 2023-12-27 Zoetis Services LLC Impfstoffs gegen maul- und klauenseuche
WO2016183370A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
US20190298824A1 (en) 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
EP3752194A4 (de) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. Zusammensetzungen und verfahren für die tumorimmuntherapie
SG11202009647VA (en) 2018-04-09 2020-10-29 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3131017C (en) 2019-02-27 2025-05-13 Actym Therapeutics, Inc. Immunostimulatory bacteria modified to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2022005705A (es) 2019-11-12 2022-08-16 Actym Therapeutics Inc Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
CN111057709A (zh) * 2019-11-13 2020-04-24 吉林农业大学 一种猪特异性CpG寡聚脱氧核苷酸及其应用
JP7740708B2 (ja) * 2019-12-25 2025-09-17 ナパジェン ファーマ，インコーポレテッド ポリデオキシアデニル酸が連結した短鎖ＣｐＧ含有オリゴデオキシヌクレオチド、該オリゴデオキシヌクレオチドを含有する複合体、及びその用途
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2001A (en) * 1841-03-12 Sawmill
US2215233A (en) * 1937-11-13 1940-09-17 Simon L Ruskin Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US3911117A (en) * 1971-12-20 1975-10-07 Fredrik Ender Raw fish and iron chelated with glutamic or ribonucleic acid in a mink diet
US3914450A (en) * 1973-04-09 1975-10-21 Anheuser Busch Concentrated extract of yeast and processes of making same
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
ES8301593A1 (es) * 1981-11-16 1983-01-01 Union Ind Y Agro Ganader S A U Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil.
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
US4741914A (en) * 1984-11-13 1988-05-03 Ajinomoto Co., Inc. Flavor enhancing seasoning containing deodorized garlic extract and process
US4956296A (en) * 1987-06-19 1990-09-11 Genex Corporation Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
JPS62275667A (ja) * 1986-05-22 1987-11-30 Ajinomoto Co Inc こく味調味料又はこく味の増強された食品の製造法
US4950652A (en) 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
DE3867308D1 (de) * 1987-05-20 1992-02-13 Chugai Pharmaceutical Co Ltd Salzersatz und dieses enthaltende nahrungsmittel.
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
JP2656571B2 (ja) * 1987-11-17 1997-09-24 三井東圧化学株式会社 テトラフェニルチオフェン誘導体およびこれを含有する電子写真用感光体
US5268365A (en) * 1988-03-11 1993-12-07 Rudolph Frederick B Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance
CA1336174C (en) * 1988-07-22 1995-07-04 Ronald Peter Potman Method for the preparation of a yeast extract said yeast extract, its use as a food flavour and a food composition comprising the yeast extract
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP1227323B2 (de) 1990-08-25 2011-01-19 Bioprocess Pty Ltd Nicht-A, nicht-B Hepatitis Virus Antigen, und diagnostische Verfahren.
US5234811A (en) * 1991-09-27 1993-08-10 The Scripps Research Institute Assay for a new gaucher disease mutation
EP0580754A1 (de) 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynukleotide und oligonukleotide, verwendbar als köder für proteine, die ausgewählt zu definierten dns-sequenzen binden
WO1992021353A1 (en) 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
US6022853A (en) * 1991-08-30 2000-02-08 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
AU3628193A (en) 1992-02-18 1993-09-13 Gesellschaft Fur Biotechnologische Forschung Mbh Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
EP0572735B1 (de) 1992-06-04 1998-11-25 VYSIS, Inc. Nukleinsäuresonden zum Nachweis von Mycoplasma fermentans
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
WO1994008004A1 (en) * 1992-10-05 1994-04-14 Hybridon, Inc. Therapeutic anti-hiv oligonucleotide and pharmaceutical
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
WO1995001097A1 (en) * 1993-06-30 1995-01-12 Board Of Regents, The University Of Texas System Nucleotide preparation and uses thereof in wound healing
US6342484B1 (en) 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US20030109469A1 (en) 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JPH09501936A (ja) 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
US5492899A (en) * 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5488039A (en) * 1994-01-10 1996-01-30 Abbott Laboratories Method for the production of an enteral formula containing ribo-nucleotides
EP0672354B1 (de) * 1994-03-18 2000-07-12 Ajinomoto Co., Inc. Proteinhaltiges Mittel zur Verbesserung der Geschmacksqualität von Lebensmitteln
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
PL321711A1 (en) 1995-02-09 1997-12-22 Icn Pharmaceuticals Methods of and compositions for controlling the cd28 expression
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
JP3580900B2 (ja) * 1995-04-20 2004-10-27 ホクレン農業協同組合連合会 α−グルコシダーゼ阻害剤を含む糖を主体とする組成物を有効成分とする食品及び飼料
DK0824588T3 (da) 1995-05-11 2004-08-16 Applied Research Systems Inhibitor af IL-6 aktivitet
US5612060A (en) * 1995-05-25 1997-03-18 Alexander; J. Wesley Enhancement of transplant graft survival through nutritional immunomodulation and immunosuppressive therapy
US5976580A (en) * 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US20030219752A1 (en) 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
GB9525902D0 (en) * 1995-12-16 1996-02-21 Zeneca Ltd Fungus
US20030078223A1 (en) 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
SK84599A3 (en) 1996-12-27 2000-07-11 Icn Pharmaceuticals G-rich oligo aptamers and methods of modulating an immune response
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU5756298A (en) 1997-04-18 1998-11-13 Gesellschaft Fur Biotechnologische Forschung Mbh Attenuated salmonella strain used as a vehicle for oral immunization
JP2000514095A (ja) 1997-04-30 2000-10-24 アイシス・ファーマシューティカルス・インコーポレーテッド 生物学的利用能を向上するためのオリゴヌクレオチド
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
DK1009413T3 (da) 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en) * 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
PL345241A1 (en) 1998-05-06 2001-12-03 Upjohn Co Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
WO1999058118A2 (en) * 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
HUP0103378A2 (hu) 1998-06-29 2001-12-28 The Procter & Gamble Co. Eldobható ürülékkezelő eszköz
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
US20010034330A1 (en) 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
EP1108017A2 (de) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH Oligonukleotide mit einem g-motif und deren verwendungen
US20020065236A1 (en) * 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
ES2394458T3 (es) * 1998-09-09 2013-01-31 Genzyme Corporation Metilación de vectores plasmídicos
US20020142974A1 (en) 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
AU766492B2 (en) 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
CA2346452A1 (en) 1998-10-05 2000-04-13 The Regents Of The University Of California Methods and adjuvants for stimulating mucosal immunity
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
AU767756C (en) * 1999-01-22 2004-08-12 Schepens Eye Research Institute, Inc., The Activation of regulatory T cells by alpha-melanocyte stimulating hormone
AU4343700A (en) * 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000062787A1 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Methods and compositions for use in potentiating antigen presentation by antigen presenting cells
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
AU4992900A (en) 1999-05-06 2000-11-21 Immune Response Corporation, The Hiv immunogenic compositions and methods
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001000232A2 (en) 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
EP2314693A3 (de) 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
IL148843A0 (en) * 1999-09-25 2002-09-12 Univ Iowa Res Found Immunostimulatory nucleic acids
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20020091095A1 (en) 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
EP1322655B1 (de) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
WO2001055341A2 (en) 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
WO2001062207A2 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20030130217A1 (en) 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
AU2001239873A1 (en) * 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
WO2001072123A1 (en) 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
US20020142978A1 (en) 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
GB0009470D0 (en) 2000-04-17 2000-06-07 Univ Southampton Materials and methods relating to immune responses to fusion proteins
AU2001274817A1 (en) 2000-05-05 2001-11-20 The Regents Of The University Of California Agents that modulate dna-pk activity and methods of use thereof
US6593511B1 (en) 2000-05-12 2003-07-15 Bioseek, Inc. Models of chronic and acute inflammatory diseases
EP1292331A2 (de) * 2000-06-07 2003-03-19 Biosynexus Incorporated Immunstimulierende rns/dns hybridmolekule
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
WO2002009645A2 (en) 2000-08-01 2002-02-07 The Johns Hopkins University Intercellular transport protein linked to an antigen as a molecular vaccine
US7811592B2 (en) 2000-08-16 2010-10-12 Auburn University Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia
EP1335741A4 (de) 2000-08-25 2005-10-26 Yeda Res & Dev METHODE ZUR PRÄVENTION VON AUTOIMMUNKRANKHEITEN MIT CpG-ENTHALTENDEN POLYNUCLEOTIDEN(04.03.02)
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP2005500806A (ja) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
ATE384072T1 (de) 2000-09-26 2008-02-15 Idera Pharmaceuticals Inc Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
MXPA03002640A (es) 2000-09-28 2003-06-19 Chiron Corp Microparticulas para la distribucion de acidos nucleicos heterologos.
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
US20030003579A1 (en) 2000-10-24 2003-01-02 Norimitsu Kadowaki Dendritic cells; methods
KR100331952B1 (ko) 2000-11-23 2002-04-09 최수일 다목적 고기능성 알칼리 용액 조성물 및 그 제조방법과 비특이 면역증강제로서의 용도
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030185848A1 (en) 2000-12-15 2003-10-02 Board Of Regents, The University Of Texas System Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia psittaci
NZ526322A (en) 2000-12-27 2005-06-24 Dynavax Tech Corp Immunomodulatory polynucleotides and methods of using the same
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CN1306956C (zh) 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
US20030096417A1 (en) 2001-06-01 2003-05-22 Fischer Laurent Bernard Vaccination against feline immunodeficiency virus
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US7547551B2 (en) 2001-06-21 2009-06-16 University Of Antwerp. Transfection of eukaryontic cells with linear polynucleotides by electroporation
EP1404873B1 (de) 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimäre immunmodulatorische verbindungen und verfahren zu deren verwendung
US7666674B2 (en) * 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
JP2005518343A (ja) 2001-08-03 2005-06-23 メダレックス， インク． 新規なｐｇｃ−１イソフォームおよびその使用媒介型免疫治療を向上させるためのその使用
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
AU2002326751A1 (en) 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
AU2002324909A1 (en) 2001-09-07 2003-03-24 Baylor College Of Medicine Linear dna fragments for gene expression
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP1451581A4 (de) 2001-10-05 2006-01-11 Coley Pharm Gmbh Agonisten und antagonisten der signalisierung des toll-ähnlichen rezeptors 3
EP1478371A4 (de) 2001-10-12 2007-11-07 Univ Iowa Res Found Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen
AU2002362019B2 (en) 2001-11-21 2007-12-20 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
CA2531280A1 (en) 2002-07-03 2004-01-15 Cambridge Scientific, Inc. Vaccines to induce mucosal immunity
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
EP1572122A4 (de) * 2002-11-01 2008-04-09 Us Gov Health & Human Serv Verfahren zur vorbeugung gegen infektionen von bioterrorismus-agentien mit immunstimulierenden cpg-oligonukleotiden
JP2008523084A (ja) * 2004-12-08 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー 免疫賦活用合剤および方法
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2007027718A1 (en) * 2005-08-31 2007-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of altering an immune response induced by cpg oligodeoxynucleotides
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides

Also Published As

Publication number Publication date
DE60131430D1 (de) 2007-12-27
US8232259B2 (en) 2012-07-31
US7521063B2 (en) 2009-04-21
EP1322655A1 (de) 2003-07-02
EP1322655B1 (de) 2007-11-14
AU2001227889A1 (en) 2001-07-24
US20030144229A1 (en) 2003-07-31
US20080069825A1 (en) 2008-03-20
US20110189267A1 (en) 2011-08-04
DE60131430T2 (de) 2008-10-16
US7919477B2 (en) 2011-04-05
WO2001051500A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
DE60131430D1 (de) Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
NL1007707A1 (nl) Alpha-Aminoacetofenonen en hun toepassing als foto-initiatoren.
DE60139401D1 (de) Erweiterung des bereichs rechnerischer körper von ganzen zahlen
DE60112595D1 (de) System zur gewichtsklassifizierung
DK1019358T4 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
ATE267184T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung zur hemmung der hormonsensitiven lipase
EP1305438A4 (de) Verbesserte virus-ähnliche partikel aufbauend auf dem hepatitis b kleinen hüllprotein
DE60235252D1 (de) Aromatische methyltransferasen und ihre verwendung
CA96874S (en) Set of flatware
NO20031860D0 (no) Kahalaolid F
DE60143665D1 (de) Support-system zur herstellung von maschenware und entsprechendes server-system
DE60141871D1 (de) Oligonukleotidmarkierungsstoffe und ihre Verwendung
DE50002530D1 (de) Nichtlineare echokompensation bei dmt-systemen
DK0633928T3 (da) Mikroorganismer, deres fremstilling og anvendelse
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
FI20000400L (fi) Viestinvälitysjärjestelmä ja vaate
ATE473002T1 (de) Zusammensetzungen zur vorbeugung von geschwüren in pferden
DK1010689T3 (da) Substituerede cycloheptener, deres fremstilling og anvendelse
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
IT1315381B1 (it) Gruppo deodorizzatore e/o profumatore d'aria
EP1315794A4 (de) Genetische demonstrationder notwendigkeit von nkx6.1, nkx2.2 und nkx6.2 zur generierung von ventralen nervenzellen
FI20000656L (fi) Hydraulijärjestelmä ja siihen sovitettava vaimennin
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1322655

Country of ref document: EP